-+ 0.00%
-+ 0.00%
-+ 0.00%

Cinclus Pharma completes Phase III HEEALING1 patient visits, guides for Q4 2026 topline data

PUBT·09/29/2026 06:03:04
Listen to the news
Cinclus Pharma completes Phase III HEEALING1 patient visits, guides for Q4 2026 topline data
  • Cinclus Pharma completed all patient visits in the Phase III HEEALING1 trial of linaprazan glurate in erosive GERD.
  • Topline results have not been presented yet; the readout is scheduled for Q4 2026.
  • The study is intended to show better healing and symptom control than standard PPI therapy, supporting a potential regulatory filing.
  • Positive data could advance European commercialization via the Zentiva license, with the company retaining US commercial rights.
  • A second Phase III trial, HEEALING2, is planned to start in the US and Europe following the HEEALING1 readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cinclus Pharma Holding AB (Publ) published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.